InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,570.64
(
-0.89%
)
US TECH 100
19,035.20
(
-1.37%
)
Dow Jones
40,712.78
(
-0.43%
)
Brent Oil
76.54
(
-0.08%
)
Bitcoin
60,727.30
(
0.59%
)
Post# of 252959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 837
Posts 120328
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: linhdtu post# 157225

Thursday, 02/21/2013 8:02:33 PM

Thursday, February 21, 2013 8:02:33 PM

Post# of 252959

AMRN—When I looked into Lovaza patent portfolio on the FDA OB site, Lovaza has only 3 patents listed whereas Vascepa has 8 currently listed and counting related to the Anchor trial.

What matters is not the quantity of patents in the Orange Book, but rather the quality. AMRN’s patents will (IMO) be challenged on the basis of obviousness.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up